Ursodeoxycholic acid

• Tablets 150mg, 250mg, 300mg (£18.00 = 60 x 250mg)
• Oral suspension sugar free 250mg/5ml (£26.98 = 250ml)

Indications and dose

• Dissolution of gallstones
  • 8–12mg/kg daily as a single dose at bedtime or in two divided doses, for up to 2 years; treatment is continued for 3–4 months after stones dissolve
• Primary biliary cirrhosis
  • 12–16mg/kg daily in 3 divided doses for 3 months, then 12–16mg/kg once daily at bedtime

Elafibranor

• Tablets 80mg

Notes

1. NICE TA1016: Elafibranor (Iqirvo) is recommended, within its marketing authorisation, as an option for treating biliary cholangitis in adults (November 2024)
   1. when used:
      1. with ursodeoxycholic acid (UDCA), if the biliary cholangitis has not responded well enough to UDCA, or
      2. alone, if UDCA cannot be tolerated.
   2. It is only recommended if the company provides it according to the commercial arrangement.

Obeticholic acid

• Tablets 5mg, 10mg

Notes

1. NICE TA443 Obeticholic acid for treating primary biliary cholangitis (April 2017) (NHS England Commissioned)

Odevixibat

• Hard capsules 200micrograms, 400micrograms, 600micrograms, 1,200micrograms

Notes

1. NICE HST17: Odevixibat (Bylvay) is recommended, within its marketing authorisation, as an option for treating progressive familial intrahepatic cholestasis (PFIC) in people 6 months and older (February 2022). It is recommended only if the company provides odevixibat according to the commercial arrangement.